{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:40:31Z","timestamp":1776328831703,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004032","name":"Parkinson Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005753","name":"Royal Physiographic Society of Lund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005753","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.nbd.2025.106841","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T11:47:12Z","timestamp":1739447232000},"page":"106841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Lack of neuroprotection after systemic administration of the soluble TNF inhibitor XPro1595 in an rAAV6-\u03b1-Syn\u00a0+\u00a0PFFs-induced rat model for Parkinson's disease"],"prefix":"10.1016","volume":"207","author":[{"given":"Filip","family":"Fredlund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Fryklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Trujeque-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah A.","family":"Staley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin C.","family":"Luk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mal\u00fa G.","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Swanberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2025.106841_bb0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JPD-140410","article-title":"Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats","volume":"4","author":"Barnum","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0010","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3233\/JPD-223452","article-title":"A combined alpha-Synuclein\/fibril (SynFib) model of Parkinson-like synucleinopathy targeting the nigrostriatal dopamine system","volume":"12","author":"Bjorklund","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.pbr.2020.02.003","article-title":"Animal models for preclinical Parkinson\u2019s research: an update and critical appraisal","volume":"252","author":"Cenci","year":"2020","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.nbd.2025.106841_bb0020","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","article-title":"Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy","volume":"29","author":"Chung","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2025.106841_bb0025","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/brain\/awr149","article-title":"GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson\u2019s disease","volume":"134","author":"Decressac","year":"2011","journal-title":"Brain."},{"key":"10.1016\/j.nbd.2025.106841_bb0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.nbd.2011.12.013","article-title":"Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons","volume":"45","author":"Decressac","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12974-019-1636-8","article-title":"Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice","volume":"16","author":"Earls","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2025.106841_bb0040","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.7150\/ijbs.4679","article-title":"Interleukin-6, a major cytokine in the central nervous system","volume":"8","author":"Erta","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.nbd.2025.106841_bb0045","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3233\/JPD-240062","article-title":"Ciita regulates local and systemic immune responses in a combined rAAV-alpha-synuclein and preformed fibril-induced rat model for Parkinson\u2019s disease","volume":"14","author":"Fredlund","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0050","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"Alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.nbd.2025.106841_bb0055","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.abf7266","article-title":"CD4(+) T cells contribute to neurodegeneration in Lewy body dementia","volume":"374","author":"Gate","year":"2021","journal-title":"Science."},{"key":"10.1016\/j.nbd.2025.106841_bb0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/B978-0-444-52001-2.00011-X","article-title":"Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation","volume":"122","author":"Gelfand","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.nbd.2025.106841_bb0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13024-019-0335-3","article-title":"Microglia affect alpha-synuclein cell-to-cell transfer in a mouse model of Parkinson\u2019s disease","volume":"14","author":"George","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2025.106841_bb0070","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JPD-202351","article-title":"T cells limit accumulation of aggregate pathology following Intrastriatal injection of alpha-Synuclein fibrils","volume":"11","author":"George","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878771","article-title":"Neuroinflammation in Parkinson\u2019s disease - putative Pathomechanisms and targets for disease-modification","volume":"13","author":"Grotemeyer","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nbd.2025.106841_bb0080","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/ng.642","article-title":"Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson\u2019s disease","volume":"42","author":"Hamza","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.nbd.2025.106841_bb0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/mt.2010.217","article-title":"Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson\u2019s disease","volume":"19","author":"Harms","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2025.106841_bb0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00401-021-02268-5","article-title":"Periphery and brain, innate and adaptive immunity in Parkinson\u2019s disease","volume":"141","author":"Harms","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2025.106841_bb0095","doi-asserted-by":"crossref","first-page":"eadk3225","DOI":"10.1126\/scitranslmed.adk3225","article-title":"Central and peripheral innate and adaptive immunity in Parkinson\u2019s disease","volume":"15","author":"Harms","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2025.106841_bb0100","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.4049\/jimmunol.180.5.3289","article-title":"Vra4 congenic rats with allelic differences in the class II transactivator gene display altered susceptibility to experimental autoimmune encephalomyelitis","volume":"180","author":"Harnesk","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.nbd.2025.106841_bb0105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2025.106841_bb0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.jnen.0000195941.48033.eb","article-title":"Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase","volume":"65","author":"Ishida","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2025.106841_bb0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2017.07.016","article-title":"Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to alpha-synuclein-induced dopaminergic neurodegeneration","volume":"106","author":"Jimenez-Ferrer","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbi.2020.10.017","article-title":"The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson\u2019s disease","volume":"91","author":"Jimenez-Ferrer","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.nbd.2025.106841_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105027","article-title":"Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson\u2019s disease: a case series","volume":"144","author":"Joers","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0130","doi-asserted-by":"crossref","first-page":"e1672","DOI":"10.1212\/WNL.0000000000011630","article-title":"Tumor necrosis factor inhibition and Parkinson disease: a Mendelian randomization study","volume":"96","author":"Kang","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.nbd.2025.106841_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/npjparkd.2015.2","article-title":"Common genetic variant association with altered HLA expression, synergy with Pyrethroid exposure, and risk for Parkinson\u2019s disease: an observational and case-control study","volume":"1","author":"Kannarkat","year":"2015","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0140","doi-asserted-by":"crossref","first-page":"16533","DOI":"10.1038\/s41598-017-15813-8","article-title":"Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice","volume":"7","author":"Karampetsou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2025.106841_bb0145","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41467-020-15626-w","article-title":"alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease","volume":"11","author":"Lindestam Arlehamn","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2025.106841_bb0150","doi-asserted-by":"crossref","first-page":"20051","DOI":"10.1073\/pnas.0908005106","article-title":"Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells","volume":"106","author":"Luk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2025.106841_bb0155","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.celrep.2016.08.053","article-title":"Molecular and biological compatibility with host alpha-Synuclein influences fibril pathogenicity","volume":"16","author":"Luk","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.nbd.2025.106841_bb0160","article-title":"Selective inhibition of soluble tumor necrosis factor alters the neuroinflammatory response following moderate spinal cord injury in mice","volume":"12","author":"Lund","year":"2023","journal-title":"Biology (Basel)."},{"key":"10.1016\/j.nbd.2025.106841_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2017.02.010","article-title":"Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice","volume":"102","author":"MacPherson","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune response mechanisms against AAV vectors in animal models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.nbd.2025.106841_bb0175","doi-asserted-by":"crossref","first-page":"9365","DOI":"10.1523\/JNEUROSCI.1504-06.2006","article-title":"Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson\u2019s disease","volume":"26","author":"McCoy","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2025.106841_bb0180","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/mt.2008.146","article-title":"Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats","volume":"16","author":"McCoy","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2025.106841_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2025.106841_bb0190","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3233\/JPD-212555","article-title":"Sequential or simultaneous injection of preformed fibrils and AAV overexpression of alpha-Synuclein are equipotent in producing relevant pathology and behavioral deficits","volume":"12","author":"Negrini","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0195","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.106841_bb0200","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2006"},{"key":"10.1016\/j.nbd.2025.106841_bb0205","series-title":"Paxinos and Watson\u2019s the Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2014"},{"key":"10.1016\/j.nbd.2025.106841_bb0210","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/ejn.14129","article-title":"Implementation of deep neural networks to count dopamine neurons in substantia nigra","volume":"48","author":"Penttinen","year":"2018","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2025.106841_bb0215","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2025.106841_bb0220","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.nbd.2025.106841_bb0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience."},{"key":"10.1016\/j.nbd.2025.106841_bb0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41531-023-00449-5","article-title":"A systematic review and meta-analysis of inflammatory biomarkers in Parkinson's disease","volume":"9","author":"Qu","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0235","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.nbd.2025.106841_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008784","article-title":"Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease","volume":"5","author":"Sanchez-Guajardo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2025.106841_bb0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-2094-5-7","article-title":"The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective","volume":"5","author":"Shaftel","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2025.106841_bb0250","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.nbd.2025.106841_bb0255","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1126\/science.1081297","article-title":"Inactivation of TNF signaling by rationally designed dominant-negative TNF variants","volume":"301","author":"Steed","year":"2003","journal-title":"Science."},{"key":"10.1016\/j.nbd.2025.106841_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.944875","article-title":"A novel automated morphological analysis of Iba1+ microglia using a deep learning assisted model","volume":"16","author":"Stetzik","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2025.106841_bb0265","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson's disease recognize alpha-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.nbd.2025.106841_bb0270","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.nbd.2025.106841_bb0275","doi-asserted-by":"crossref","first-page":"E8284","DOI":"10.1073\/pnas.1710442114","article-title":"Modeling Parkinson\u2019s disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain","volume":"114","author":"Thakur","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2025.106841_bb0280","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/NEN.0b013e31818e5e99","article-title":"Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease","volume":"67","author":"Theodore","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2025.106841_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105700","article-title":"Immune responses in the Parkinson\u2019s disease brain","volume":"168","author":"Weiss","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2025.106841_bb0290","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-018-1286-2","article-title":"Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson\u2019s disease","volume":"15","author":"Williams","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2025.106841_bb0295","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ajhg.2013.10.009","article-title":"Association of Parkinson disease with structural and regulatory variants in the HLA region","volume":"93","author":"Wissemann","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.nbd.2025.106841_bb0300","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41531-021-00231-5","article-title":"Fine mapping of the HLA locus in Parkinson's disease in Europeans","volume":"7","author":"Yu","year":"2021","journal-title":"NPJ Parkinsons Dis."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996125000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996125000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:51:42Z","timestamp":1766083902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996125000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":60,"alternative-id":["S0969996125000579"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2025.106841","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.23.619575","asserted-by":"object"}]},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of neuroprotection after systemic administration of the soluble TNF inhibitor XPro1595 in an rAAV6-\u03b1-Syn\u00a0+\u00a0PFFs-induced rat model for Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2025.106841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106841"}}